AnaptysBio, Inc. (ANAB) stock rallied over 0.76% intraday to trade at $22.62 a share on NASDAQ. The stock opened with a gain of 2.86% at $22.57 and touched an intraday high of $23.12, rising 0.76% against the last close of $22.45. The stock went to a low of $21.89 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue63.17 Million
5Y Sales Change30.50%
Fiscal Year Ends2021-12-30
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
AnaptysBio, Inc. (NASDAQ: ANAB) stock price is $22.62 as of the last check on Thursday, June 23. During the trading session, ANAB stock reached the peak price of $23.12 while $21.89 was the lowest point it dropped to.
The NASDAQ listed ANAB is part of Biotechnology industry that operates in the broader Health Care sector. AnaptysBio, Inc. , a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
Mr. Hamza Suria
Pres, CEO & Director
Mr. Dennis M. Mulroy
Chief Financial Officer
Mr. Hamza Suria M.B.A., M.Sc.
Dr. Paul F. Lizzul
Chief Medical Officer
ANAB stock traded closed the last session at $22.62, which is $0.17 or 0.76% lower than its previous close of $22.45. ANAB's current trading price is 24.29% lower than its 52-week high of $37.89 where as its distance from 52-week low of 18.20% is -40.30%.
Number of ANAB employees currently stands at -. ANAB operates from 10770 Wateridge Circle, Suite 210, San Diego, CA 92121-5801, United States.
Official Webiste of $ANAB is: https://www.anaptysbio.com
ANAB stock volume for the day was 178,449 shares while in the previous session number of ANAB shares traded was 178,400 . The average number of ANAB shares traded daily for last 3 months was 346.74 Thousands.
The percentage change in ANAB stock occurred in the recent session was 0.76% while the dollar amount for the price change in ANAB stock was $0.17.
In the recent session, the day high for ANAB stock was $23.12 while the low for ANAB stock touched on the day was $21.89.
The market value of ANAB currently stands at 605.99 Million with its latest stock price at $22.62 and 27.71 Million of its shares outstanding.